Evidence map›Paper›PMID 27444582›Full record

ArticleBMC surgery2016

The value of hepatic resection in metastasic renal cancer in the Era of Tyrosinkinase Inhibitor Therapy.

Hans Michael Hau, Florian Thalmann, Christoph Lübbert, Mehmet Haluk Morgul, Moritz Schmelzle, Georgi Atanasov, Christian Benzing, Undine Lange, Rudolf Ascherl, Roman Ganzer and 4 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC surgery, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 1 country.

Hans Michael HauDepartment of Visceral, Transplantation, Vascular and Thoracic Surgery, University Hospital of Leipzig, Liebigstrasse 20, 04103, Leipzig, Germany. HansMichael.Hau@medizin.uni-leipzig.de.
Florian ThalmannDepartment of Visceral, Transplantation, Vascular and Thoracic Surgery, University Hospital of Leipzig, Liebigstrasse 20, 04103, Leipzig, Germany.
Christoph LübbertDivision of Infectious Diseases and Tropical Medicine, Department of Gastroenterology and Rheumatology, Leipzig University Hospital, Leipzig, Germany.
Mehmet Haluk MorgulDepartment of Visceral, Transplantation, Vascular and Thoracic Surgery, University Hospital of Leipzig, Liebigstrasse 20, 04103, Leipzig, Germany.
Moritz SchmelzleDepartment of General, Visceral and Transplant Surgery, Campus Virchow, Charité-Universitätsmedizin Berlin, Augustenburger Platz 1, Berlin, Germany.
Georgi AtanasovDepartment of General, Visceral and Transplant Surgery, Campus Virchow, Charité-Universitätsmedizin Berlin, Augustenburger Platz 1, Berlin, Germany.
Christian BenzingDepartment of General, Visceral and Transplant Surgery, Campus Virchow, Charité-Universitätsmedizin Berlin, Augustenburger Platz 1, Berlin, Germany.
Undine LangeDepartment of Visceral, Transplantation, Vascular and Thoracic Surgery, University Hospital of Leipzig, Liebigstrasse 20, 04103, Leipzig, Germany.
Rudolf AscherlDepartment of Visceral, Transplantation, Vascular and Thoracic Surgery, University Hospital of Leipzig, Liebigstrasse 20, 04103, Leipzig, Germany.
Roman GanzerDepartment of Urology, University of Leipzig, Leipzig, Germany.
Dirk UhlmannDepartment of Visceral, Transplantation, Vascular and Thoracic Surgery, University Hospital of Leipzig, Liebigstrasse 20, 04103, Leipzig, Germany.
Hans-Michael TautenhahnDepartment of Visceral, Transplantation, Vascular and Thoracic Surgery, University Hospital of Leipzig, Liebigstrasse 20, 04103, Leipzig, Germany.
Georg WiltbergerDepartment of Visceral, Transplantation, Vascular and Thoracic Surgery, University Hospital of Leipzig, Liebigstrasse 20, 04103, Leipzig, Germany.
Michael BartelsDepartment of Visceral, Transplantation, Vascular and Thoracic Surgery, University Hospital of Leipzig, Liebigstrasse 20, 04103, Leipzig, Germany.
University Hospital Leipzig · DECharité - Universitätsmedizin Berlin · DELeipzig University · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe value of liver-directed therapy (LDT) in patients with metastasic renal cell carcinoma (MRCC) is still an active field of research, particularly in the era of tyrosinkinase inhibitor (TKI) therapy.

methodsThe records of 35 patients with MRCC undergoing LDT of metastasic liver lesions between 1992 and 2015 were retrospectively analyzed. Immediate postoperative TKI was given in a subgroup of patients after LDT for metastasic lesions. Uni- and multivariate models were applied to assess overall survival (OS), progression-free survival (PFS) and disease-free survival (DFS).

resultsFollowing primary tumor (renal cell cancer) resection and LDT, respectively, median OS was better for a total of 16 patients (41 %) receiving immediate postoperative TKI with 151 and 98 months, when compared to patients without TKI therapy with 61 (p = 0.003) and 40 months (p = 0.032). Immediate postoperative TKI was associated with better median PFS (47 months versus 19 months; p = 0.023), whereas in DFS only a trend was observed (51 months versus 19 months; p = 0.110).

conclusionsLDT should be considered as a suitable additive tool in the era of TKI therapy of MRCC to the liver. In this context, postoperative TKI therapy seems to be associated with better OS and PFS, but not DFS.

Indexed as

HepatectomyAgedCarcinoma, Renal CellDisease-Free SurvivalFemaleHumansKidney NeoplasmsMaleMiddle AgedProtein Kinase InhibitorsProtein-Tyrosine KinasesRetrospective StudiesSurvival RateProtein Kinase InhibitorsProtein-Tyrosine KinasesLiver resectionMetastasic renal cancerTyrosinkinase inhibitor agents

Identifiers

PMID27444582
PMCPMC4957271
OpenAlexW2490803725

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.